1. Home
  2. ANNX vs SCZM Comparison

ANNX vs SCZM Comparison

Compare ANNX & SCZM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annexon Inc.

ANNX

Annexon Inc.

SELL

Current Price

$3.96

Market Cap

873.3M

Sector

Health Care

ML Signal

SELL

Logo Santacruz Silver Mining Ltd. Common Shares

SCZM

Santacruz Silver Mining Ltd. Common Shares

SELL

Current Price

$8.85

Market Cap

847.1M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
ANNX
SCZM
Founded
2011
N/A
Country
United States
Canada
Employees
N/A
455
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
873.3M
847.1M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ANNX
SCZM
Price
$3.96
$8.85
Analyst Decision
Buy
Buy
Analyst Count
10
2
Target Price
$15.43
★ $16.97
AVG Volume (30 Days)
★ 3.0M
394.8K
Earning Date
11-09-2026
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$49.99
Revenue Next Year
N/A
$12.57
P/E Ratio
★ N/A
$14.27
Revenue Growth
N/A
N/A
52 Week Low
$2.54
$5.61
52 Week High
$7.18
$17.65

Technical Indicators

Market Signals
Indicator
ANNX
SCZM
Relative Strength Index (RSI) 40.56 48.89
Support Level $3.71 $8.55
Resistance Level $4.37 $9.05
Average True Range (ATR) 0.23 0.44
MACD 0.04 -0.03
Stochastic Oscillator 45.33 47.62

Price Performance

Historical Comparison
ANNX
SCZM

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About SCZM Santacruz Silver Mining Ltd. Common Shares

Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapa mine and processing plant, and Corporate and Other activities. Key revenue is generated from Zimapan.

Share on Social Networks: